Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer

Published:2018-07-01 Issue:7 Volume:4 Page:944
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Armstrong Andrew J.¹²³,Anand Aseem⁴⁵,Edenbrandt Lars⁴⁶,Bondesson Eva⁴,Bjartell Anders⁵,Widmark Anders⁷,Sternberg Cora N.⁸⁹,Pili Roberto¹⁰,Tuvesson Helen¹¹,Nordle Örjan¹²,Carducci Michael A.¹³,Morris Michael J.¹⁴¹⁵

Affiliation:

1. Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina

2. Division of Urology, Department of Surgery, Duke Cancer Institute, Duke University, Durham, North Carolina

3. Department of Pharmacology and Cancer Biology, Duke Cancer Institute, Duke University, Durham, North Carolina

4. EXINI Diagnostics AB, Lund, Sweden

5. Division of Urological Cancers, Department of Translational Medicine, Lund University, Malmö, Sweden

6. Department of Nuclear Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

7. Umeå University, Umeå, Sweden

8. San Camillo Hospital, Rome, Italy

9. Forlanini Hospital, Rome, Italy

10. Indiana University School of Medicine, Indianapolis

11. Active Biotech AB, Lund, Sweden

12. Nordle Biostatistical Consultancy, Rydebäck, Sweden

13. The John Hopkins University School of Medicine, Baltimore, Maryland

14. Memorial Sloan Kettering Cancer Center, New York, New York

15. Weill Cornell Medicine, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference20 articles.

1. Characterising the castration-resistant prostate cancer population: a systematic review.;Kirby;Int J Clin Pract,2011

2. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.;Scher;J Clin Oncol,2016

3. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.;Imbriaco;Clin Cancer Res,1998

4. Bone Scan Index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.;Dennis;J Clin Oncol,2012

5. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.;Sabbatini;J Clin Oncol,1999

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra;Cancers;2024-07-29

2. Quantitative analysis of liver standardized uptake value repeatability in SPECT/CT implications for clinical practice;Biomedical Physics & Engineering Express;2024-04-04

3. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment;Annals of Nuclear Medicine;2024-03-22

4. Advances in the study of S100A9 in cardiovascular diseases;Cell Proliferation;2024-03-19

5. Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer;Annals of Nuclear Medicine;2024-03-13